ITOT closely tracks the S&P 500, with 90% of its holdings overlapping, making it largely redundant for long-term investors in ...

Dianthus Therapeutics announces positive Phase II results for Claseprubart in myasthenia gravis, highlighting best-in-class potential.

Grafting surface loops containing antibody epitopes of a poorly expressed flu neuraminidase protein onto a high-expressing, stable scaffold improves its production and stability for vaccine ...